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and in the afternoon (7 h after last application – t3)) in order 
to detect a possible immediate or summative (in the after-
noon) heroin effect on these two neuropeptides. Moreover, 
we investigated possible associations between the serum 
levels of these neurotrophic growth factors and psychomet-
ric dimensions of addictive behavior, e.g. craving, withdraw-
al, depression. Whereas there was no direct effect of DAM 
application on the serum levels of both neurotrophic growth 
factors neither in the morning nor in the afternoon, the NGF 
serum levels of the patient group were found to be signifi-
cantly increased at all four time points of investigation com-
pared with the healthy controls. In contrast, VEGF-A serum 
levels did not differ significantly in the patient and control 
groups. We found a significant positive association between 
the NGF serum levels and several items of the short opiate 
withdrawal scale as well as a negative association between 
self-reported mood (measured by visual analogue scale) and 
mood before heroin application (in the morning as in the 
afternoon). Moreover, we found a significant positive asso-
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 Abstract 
 Preclinical study results suggest that neurotrophic peptides 
like nerve growth factor (NGF) and vascular endothelial 
growth factor A (VEGF-A) may be associated with symptoms 
of addictive behavior like withdrawal symptoms and reward-
ing effects. We investigated alterations in NGF and VEGF-A 
serum levels in opiate-dependent patients (25 male pa-
tients), who received diamorphine (DAM, heroin) treatment 
within a structured opiate maintenance program, and com-
pared the results with the NGF and VEGF-A serum levels of 
healthy controls (23 male controls). NGF and VEGF-A serum 
levels were assessed before and after DAM administration 
twice a day (in the morning (16 h after last application – t1) 
 Received: August 29, 2011 
 Accepted: February 7, 2012 
 Published online: April 20, 2012 
European
Addiction
cRe es ar h
 Annemarie Heberlein, MD 
 Center for Addiction Research, Department of Psychiatry ,  Social Psychiatry and 
Psychotherapy, Hannover Medical School 
 Carl-Neuberg-Strasse 1, DE–30625 Hannover (Germany) 
 Tel. +49 1761 532 2402, E-Mail heberlein.annemarie   @   mh-hannover.de 
 © 2012 S. Karger AG, Basel
1022–6877/12/0185–0213$38.00/0 
 Accessible online at:
www.karger.com/ear 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
16
/2
01
6 
4:
51
:3
9 
PM
 Heberlein et al. Eur Addict Res 2012;18:213–219214
ciation between the NGF serum levels (t1 and t3) and the 
self-reported craving for methadone. In contrast, we found 
a negative association between the VEGF-A serum levels and 
avoidance, anxiety, suicide intentions of the SCL-90 as well as 
a positive association between the VEGF-A serum levels and 
the subscales of the heroin craving questionnaire measuring 
the rewarding effects of heroin. In conclusion, the results of 
this pilot study show that there might be an association be-
tween symptoms of opiate dependence and withdrawal and 
serum levels of VEGF-A and NGF. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Opiates, in particular heroin, are known for their high 
addictive potential which may be tracked back, on the 
neurobiological level, to the activation of mesolimbic and 
mesocortical dopamine neurons as well as to subsequent 
alterations in midbrain dopamine release  [1, 2] . On the 
bio-behavioral level, use of heroin typically results in a 
period of euphoria and tension relief  [3] , which is fol-
lowed by a period of dysphoria and increase in tension 
when heroin’s stimulating effects are fading  [4] . Dyspho-
ria and increase in tension – as bodily symptoms like lac-
rimation, headache, muscle cramps and increase of blood 
pressure – are typical symptoms of the opiate withdraw-
al syndrome. Heroin’s short half-life of approximately 
4–6 h causes the recurrence of typical opiate withdrawal 
symptoms in opiate-dependent patients, which is one 
reason for the need of recurrent drug consume and its 
social implications  [5] .
 Actual research results confirm that neurotrophic 
growth factors like nerve growth factor (NGF) are in-
volved in the regulation of midbrain dopamine release 
 [6] . Moreover, clinical studies suggest that neurotrophic 
growth factors may be associated with mood symptoms 
like antidepressant effects (vascular endothelial growth 
factor A, VEGF-A) or stress (NGF). For example, an in-
crease in circulating NGF levels has been observed in 
combating male mice  [7] and, in particular, higher NGF 
serum levels have been observed in defeated, subordinat-
ed compared to dominant mice supporting the hypoth-
esis of an association between NGF serum levels and 
stressful life events  [8] . Consistently, in parachuters’ NGF 
serum levels were reported to increase just before their 
first jump  [9] . These and further study results  [10] suggest 
that alterations of NGF may be part of the neurobiologi-
cal stress cascade. This hypothesis is further strength-
ened by some preclinical study results that report about 
an association between cortisol serum levels and NGF 
serum levels  [11] . Therefore, one could speculate that 
there might be an association between withdrawal symp-
toms and NGF serum levels as well. Consistent with such 
a hypothesis, we found increased NGF serum levels in 
alcohol-dependent patients, which decreased during al-
cohol withdrawal  [12, 13] .
 Although the expression of the angiogenic VEGF-A 
has been shown to be associated with the expression of 
NGF  [14] , clinical study results suggest different associa-
tions between VEGF-A and mood compared to NGF’s 
effects. In particular, the results given point towards an 
association between VEGF-A and antidepressant effects 
 [15] and that polymorphisms of the VEGF-A gene may be 
relevant for the therapeutic outcome of antidepressant 
treatment  [16] .
 With respect to such study results, we aimed to inves-
tigate putative associations between psychometric mea-
surements of opiate reward and opiate withdrawal in opi-
ate-dependent patients in a structured diamorphine 
(DAM) maintenance program.
 Subjects and Methods 
 We investigated 25 opiate-dependent male patients (see  table 1 
for details) recruited from the Heroin Prescription Center of the 
Psychiatric Hospital of the University of Basel  [17] . All patients 
fulfilled the diagnostic criteria of opiate dependence according to 
ICD-10 and DSM-IV, and had participated in a DAM mainte-
nance program for at least 2 months before participating in the 
study. All patients received individual doses of injectable DAM 
(administered intravenously or intramuscularly) twice a day. Ad-
ditionally, 8 patients received oral methadone (mean 22.85 mg, 
SD 14.1 mg) and 7 patients oral DAM treatment (mean 300.0 mg, 
SD 173.21 mg). Patients suffering from axis-I diagnoses other 
than opiate dependence and substance abuse were excluded from 
the study, as were patients showing positive breath alcohol con-
centrations. The study adhered to the Declaration of Helsinki and 
was approved by the Ethics Committee of the University of Basel. 
All patients gave written informed consent.
 General Procedures 
 All patients underwent a 1-day experiment consisting of a 
morning and an afternoon testing session at the clinic. The pro-
cedures were scheduled to guarantee that patients could admin-
ister their DAM injections at the regular time, with an interval 
of 16  8 1 h since the last DAM injection for the morning and a 
7-hour interval for the afternoon session. The individual day of 
testing was randomly allocated during a 2-week study period, 
except for Saturdays which were reserved for those working. On 
admission, breath-alcohol content was measured using a breath-
alyzer (Dräger Alcotest 7410 Plus, Germany) in order to verify 
alcohol abstinence. Participants then chose a sealed envelope 
containing five sets of self-report measures. After completing 
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the initial set of self-report instruments, the first blood sampling 
occurred. 5 min later, patients self-injected their prescribed dose 
of DAM as usual. 5 min after injection, patients were adminis-
tered the second set of measures. 45 min thereafter the second 
blood sampling was performed. Patients then completed the 
next set of instruments (administered only once during the ex-
periment).
 In the afternoon, the testing followed the same protocol, ex-
cept that patients had to deliver a urine sample at the end of test-
ing and received their monetary compensation.
 Laboratory Analyses 
 Urine samples were analyzed by the Clinical Chemical Labo-
ratory of the University Hospital Basel for the presence of alcohol, 
amphetamines, barbiturates, benzodiazepines, cannabinoids, co-
caine, ecstasy, methadone and opiates using enzyme immuno-
assays.
 NGF and VEGF-A serum levels were investigated directly be-
fore and 45 min after regular injection of DAM in the morning 
(time frame of last injection 16 h (t1 and t2)) and in the afternoon 
(7 h after the morning injection (t3 and t4)). NGF and VEGF-A 
were assessed using the DuoSet enzyme-linked immunosorbent 
assay (ELISA) Development System (DY256, DY293 B; R&D Sys-
tems, Wiesbaden-Nordenstadt, Germany). All the assays were 
performed according to the manufacturer’s instructions.
 NGF and VEGF-A serum levels obtained in the opiate-depen-
dent patients were compared to the NGF and VEGF-A serum
levels of healthy controls (23 healthy male controls, mean age 
27.90 years, SD 3.35 years). Controls were screened for substance 
abuse as well as for axis-I diagnoses using a structured interview. 
Controls were negative for axis-I diagnoses according to ICD-10 
or DSM-IV. All controls and patients investigated were Cauca-
sians.
 Patient-Rated Measurements 
 All patients completed a battery of standardized self-comple-
tion instruments presented in paper-and-pencil format. The or-
der of instruments, administered twice pre- and post-injection, 
was counterbalanced across participants and design, and includ-
ed two visual analogue scales (VAS) – the Heroin Craving Ques-
tionnaire  [18] and the Short Opiate Withdrawal Scale  [19] . Addi-
tionally, patients completed once during testing a set of question-
naires in random order, including the Substance Use History 
Form, the Center of Epidemiologic Studies – Depression Scale 
 [20] and the Symptom Checklist-27  [21] .
 Visual Analogue Scales. Patients rated their current state of 
heroin craving on a 100-mm horizontal line labeled from ‘no 
craving at all’ to ‘very strong craving’. Furthermore, participants 
responded to a 100-mm mood VAS (‘How is your general mood 
right now?’) anchored with a sad face at the left end and a happy 
face at the right end.
 Heroin Craving Questionnaire (HCQ). This multidimensional 
questionnaire presents 45 items rated on a 7-point scale from 
‘strongly disagree’ to ‘strongly agree’. Scoring yields 5 theory-de-
rived subscales, measuring different aspects of craving.
 Short Opiate Withdrawal Scale (SOWS) . This 10-item scale as-
sesses symptoms of opioid withdrawal on a 4-point intensity scale 
from ‘none’ to ‘severe’.
 Symptom Checklist-27 (SCL-27) . This modification of the Ger-
man Symptom Checklist-90-R screens for psychiatric symptoms 
on six subscales. Items are rated on a 5-point Likert scale, ranging 
from ‘not at all’ to ‘extremely’.
 Statistical Analyses 
 VEGF-A serum levels were normally distributed according to 
the Kolmogorov-Smirnov test. NGF serum levels were ln-trans-
formed in order to reach normal distribution. Correlations be-
tween the VEGF-A and the ln-transformed NGF serum levels and 
the psychometric dimensions of heroin craving were calculated 
using Pearson’s correlation coefficient. Differences between the 
VEGF-A and the ln-transformed NGF serum levels of the opiate-
dependent patients and the healthy control group were calculated 
using the t test for independent samples. Alterations of the ln-
transformed NGF and VEGF-A serum levels before and after the 
injection of DAM were assessed using the t test for dependent 
samples. The data was analyzed using PASW Statistics 18.0 and 
Graph Pad Prism TM 5.0 (Graph Pad Software Inc., San Diego, 
 Calif., USA).
Table 1.  Demographic data of the heroin-dependent patients and 
the healthy controls
Heroin-addicted 
patients (n = 28)
Healthy con-
trols (n = 43)
Mean age, years 41.2586.4 24.9384.21
Range 28454 18437
Age of first use, years
Range
19.8685.35
13435
NA
Average daily dose of
DAM, mg 323.218122.26 NA
SOWS score
t1 19.0785.93 NA
t2 12.0082.76 NA
t3 12.5382.70 NA
t4 12.9181.91 NA
Mean HCQ
t1 5.2880.79 NA
t2 3.5681.12 NA
t3 4.9580.88 NA
t4 3.5581.21 NA
SCL – total score 18.82815.13 NA
NGF
t1 237.098250.5 109.148145.35
t2 238.518260.81
t3 262.718293.79
t4 245.418314.20
VEGF-A
t1 62.59842.18 49.51842.33
t2 66.15850.44
t3 65.95841.82
t4 62.40844.08
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 Results 
 VEGF-A serum levels were not associated with the du-
ration of opiate dependence, age, or dosage of DAM or 
methadone, respectively (data not shown). The ln-trans-
formed NGF serum levels showed a trend towards a neg-
ative association with the duration of opiate dependence 
(r = –0.388, p = 0.056). The ln-transformed NGF serum 
levels were not associated with the age of the patients or 
the dosage of DAM injected (data not shown). There was 
a significant association between the dosage of metha-
done and NGF serum levels at each time point of investi-
gation (t1: r = 0.434, p = 0.021; t2: r = 0.627, p  ! 0.001; t3: 
r = 0.422, p = 0.028; t4: r = 0.442, p = 0.021). 
 (a) Comparison of the NGF and VEGF-A serum levels 
of the patients and the control group: NGF serum levels 
were significantly increased in the opiate-dependent pa-
tients before and after the application of DAM in the 
morning as in the afternoon (T = 2.483, p = 0.017 (t1);
T = 2.394, p = 0.022 (t2); T = 2.569, p = 0.015 (t3); T = 
2.150, p = 0.039 (t4)). VEGF-A serum levels were not sig-
nificantly increased compared to the serum levels of the 
healthy controls either before and after DAM injection in 
the morning or in the afternoon (see  table 1 for details). 
There was no significant difference in the NGF or VEGF-
A serum levels of patients receiving additional metha-
done compared with patients receiving a monotherapy 
with DAM (data not shown).
 (b) Alterations of the NGF and VEGF-A serum levels 
after application of DAM: Comparison of the NGF and 
VEGF-A serum levels before and after injection of the 
regular dosage of DAM showed no significant differenc-
es in the morning or in the afternoon (see  table 1 for de-
tails). NGF and VEGF-A serum levels were not associated 
with each other ( fig. 1 ,  2 ). 
 (c) Association between psychometric dimensions of 
opiate dependence and the NGF and VEGF-A serum lev-
els.
 Nerve Growth Factor 
 NGF serum levels were significantly associated with 
nausea (r = 0.545, p = 0.003), lacrimation and running 
nose (r = 0.378, p = 0.047) at t1, with nausea (r = 0.510,
p = 0.006), gastrospasm (r = 0.381, p = 0.50), sensations of 
heat and cold (r = 0.469, p = 0.040), muscle spasm (r = 
0.543, p = 0.003), lacrimation and running nose (r = 
0.722, p  ! 0.001) at t2, lacrimation and running nose (r = 
0.626, p  ! 0.001) at t3 and (r = 0.515, p  ! 0.001) at t4. More-
over, there was a negative correlation between the VAS 
measurements of mood and NGF serum levels on t1 (r = 
–0.537, p = 0.003) and t3 (r = –0.356, p = 0.068). 
 NGF serum levels on t1 (r = 0.725, p  ! 0.001) and t3
(r = 0.385, p = 0.047) were significantly associated with 
craving for methadone measured by VAS (there was no 
association with VAS measuring craving for heroin, al-
cohol and cocaine). Associations between opiate with-
drawal and NGF serum levels as well as between mood 
300
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g
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NGF2 NGF3
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A
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 Fig. 1. Means and SEM of NGF serum levels before (NGF, NGF3) 
and after (NGF2, NGF4) the scheduled injection of DAM in opi-
ate-dependent patients compared to healthy controls. 
 Fig. 2. Means and SEM of the VEGF-A serum levels before (VEGF, 
VEGF3) and after (VEGF2, VEGF4) the scheduled injection of 
DAM in opiate-dependent patients compared to healthy controls. 
VEGF-A serum levels found in the patient group did not differ 
significantly from the VEGF-A serum levels obtained from 
healthy controls. 
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and NGF serum levels were found in patients with and 
without additional methadone treatment (data not 
shown). 
 Vascular Endothelial Growth Factor A 
 There was a negative association between the VEGF-A 
serum levels and avoidance (r = –0.719, p = 0.019), anxiety 
(r = –0.718, p = 0.019), suicide intentions (r = –0.704, p = 
0.023) of the SCL-90.
 VEGF-A serum levels were significantly associated 
with the subscale measuring desire for heroin at t2 (r = 
0.712, p = 0.014) and t4 (r = 0.834, p = 0.003), anticipation 
of heroin effects at t2 (r = 0.701, p = 0.016) and at t4 (r = 
0.785, p = 0.007) and the intention of application of her-
oin at t2 (r = 0.590, p = 0.056) and t4 (r = 0.681, p = 0.030).
 Comparison between psychometric dimensions be-
tween patients receiving additional methadone and pa-
tients being treated with a monotherapy of DAM.
 Patients receiving additional methadone rated their 
actual mood worse at t1 (t = –2.249, p = 0.033) and t4
(t4 = –4.992, p  ! 0.001) than patients being treated with 
a monotherapy of DAM. Moreover, the methadone group 
showed a significant increase in SCL-90 point score (t = 
3.454, p = 0.002). There were no further significant dif-
ferences in the psychometric measurements of the two 
subgroups (data not shown).
 Discussion 
 In this pilot study, we found increased serum levels
of NGF in the opiate-dependent patients during DAM 
maintenance, whereas the VEGF-A serum levels were 
not significantly changed as compared to healthy con-
trols. According to clinical study results describing a 
negative association between VEGF-A serum levels and 
depression, we found a negative association between 
negative emotions like anxiety, avoidance and suicide 
intentions and the VEGF-A serum levels in the opiate-
dependent patients. Moreover, we found a positive as-
sociation between some aspects of heroin craving, like 
the desire for and the anticipation of desirable heroin 
effects, and the VEGF-A serum levels measured direct-
ly after application of DAM in the morning (t2) and in 
the afternoon (t4). This observation is consistent with 
the putative association between VEGF-A and depres-
sion reported before  [15, 16, 22] . These results suggest 
that the angiogenic factor VEGF-A may be directly in-
volved in the perception and/or constitution of positive 
DAM effects, although the neurobiological mechanisms 
that may explain this association are not fully under-
stood. Recent research indicates that there is not only an 
association between VEGF-A and hippocampal growth 
but also an association between VEGF-A and signaling 
pathways that are related to anxiety and depression  [23] . 
Therefore, VEGF-A may not only take influence on the 
development of addictive behavior by procession of hip-
pocampal neuronal cell growth necessary for the con-
solidation of memory  [24] , but may also directly impact 
the consolidation of rewarding drug effects by long-
term potentiation of synaptic strength. A putative im-
pact of VEGF-A in long-term alterations of intersynap-
tic communication of signaling pathways related to anx-
iety and depression would explain that an association 
between psychometric dimensions of anxiety and de-
pression are not only found in patients but also in healthy 
students  [25] , although the association observed in this 
study between the rewarding and relieving effects of 
heroin and the VEGF-A serum levels following applica-
tion of DAM in the morning (t2) and in the afternoon 
(t3) may point towards neuroadaptive processes in the 
VEGF-A signaling system due to recurrent DAM (or 
heroin) application.
 In contrast to the negative association between anxi-
ety and VEGF-A serum levels, we found a positive asso-
ciation between the (increased) NGF serum levels and 
symptoms of opiate withdrawal measured by the SOWS. 
Consistent with this finding, we found a negative correla-
tion between the VAS measuring the actual mood and 
NGF serum levels before application of DAM in the 
morning (t1) and in the afternoon (t3). Therefore, pre-
suming an indicative function of NGF and stress as sug-
gested by various studies  [9, 11] , the increased NGF serum 
levels in the patients participating in the structured DAM 
maintenance program may point towards a high level of 
stress most likely induced by recurrent opiate withdraw-
al symptoms based on the short half-life of DAM. This 
hypothesis is strengthened by the association between 
the NGF serum levels of the patient group and the craving 
for the methadone before application of DAM in the 
morning (t1) as in the afternoon (t3). This selective asso-
ciation between the NGF serum levels and methadone 
(and the lack of a similar association between the NGF 
serum levels and the craving for alcohol, cocaine or her-
oin) may be explained by the long half-life of methadone 
and its long-lasting prevention of opiate withdrawal 
symptoms.
 In conclusion, both VEGF-A and NGF serum levels 
may be useful as potential biomarkers of opiate craving 
and withdrawal. Although this study has several limita-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
16
/2
01
6 
4:
51
:3
9 
PM
 Heberlein et al. Eur Addict Res 2012;18:213–219218
tions which have to be addressed, we investigated periph-
eral VEGF-A and NGF serum levels, but until today it is 
not clear whether the peripheral blood levels of these neu-
rotrophic growth factors are related to the intracerebral 
levels of these neuropeptides. Further, both growth fac-
tors are known to be associated with cytokine regulation 
 [26, 27] . Therefore, inflammatory processes may have in-
fluenced the serum levels of both growth factors investi-
gated in this study, which we did not control. Moreover, 
as is typical for opiate-dependent patients treated with 
DAM  [28, 29] , patients enrolled in this study were not 
only treated with DAM but also with further substances 
like methadone or antidepressants. Urine samples re-
vealed that the patients also consumed further psychotro-
phic substances like benzodiazepines and amphetamines. 
Therefore, it cannot be ruled out that our results may be 
biased by this kind of ‘comedication’ typical for patients 
suffering from polytoxicomania  [30] .
 Regarding the association between NGF and stress 
and the negative association between VEGF-A and anxi-
ety and depression, our results fit well with former pre-
clinical and clinical study results. Moreover, the associa-
tions found in this study are consistent with typical clin-
ical symptoms of opiate dependence, for example the 
selectivity of the association between NGF serum levels 
and symptoms of opiate withdrawal at t1 and t3 of the 
investigation, which follow a period of abstinence of sev-
eral hours, bolster the relevance of our findings.
 In conclusion, our results point towards a potential as-
sociation between peripheral serum levels of the neuro-
trophic growth factors VEGF-A and NGF and symptoms 
of opiate dependence in patients treated with DAM. Fur-
ther studies will be necessary to validate the intriguing 
findings of our study and to enhance the understanding 
of the relevance of neurotrophic growth factors for the 
opiate dependence.
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